RxDoctor Payments Data

Logan Handwerk, PA

Physician Assistant · New York, NYNPI 1164031878

Payments from drug & device makers

$949in general payments, 2019–2025

Across 36 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$347
  • AbbVie$139
  • Gilead$103
  • Lilly USA, LLC$76
  • Novo Nordisk$53
  • Otsuka America Pharmaceutical, Inc.$51
  • plus $180 from 5 others

What the payments were for

  • Food & beverage$93899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$949 in reported general payments places this provider in the 75th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$7,450
Medicare patients
38
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala34$151,780
PrezistaDarunavir15$28,176
TivicayDolutegravir Sodium13$27,372
IsentressRaltegravir Potassium12$22,482
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)11$10,741
ValacyclovirValacyclovir Hcl11$994
Rosuvastatin Calcium73$408
Atorvastatin Calcium45$385
Nadolol13$369
Fluticasone Propionate21$283
Zolpidem Tartrate25$227
Losartan Potassium23$210
Levothyroxine Sodium14$196
Acyclovir19$134
Lisinopril24$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$103$151,78034 claims
Viiv Healthcare CompanyTivicay$347$27,37213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →